Cerebrospinal Fluid Biomarkers Profiling in Cerebral Amyloid Angiopathy and Relationship With Disease Phenotypes.

ABSTRACT:

Background

Cerebral amyloid angiopathy (CAA) is a heterogeneous small vessel disease that can occur independently or alongside Alzheimer disease (AD). CAA is diagnosed using the Boston Criteria 2.0, integrating clinical and neuroimaging features, whereas the Cerebrospinal Fluid (CSF) role in clinical practice remains under investigation. This study explores whether CSF biomarkers can identify distinct disease phenotypes, supporting hemorrhagic risk stratification.

Methods

We enrolled probable patients with CAA retrospectively (Boston Criteria 2.0) from 2 institutions, collecting clinical, neuroimaging, and follow-up data alongside core CSF biomarkers (Aβ40 [amyloid β 1-40], Aβ42 [amyloid β 1-42], p-Tau181 [phosphorylated Tau], total-Tau). Patients with CAA were stratified ap

SUBMITTER: Losa M 

PROVIDER: S-EPMC12684604 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature